Hospital
Uhs of Oklahoma, LLC
Uhs of Oklahoma, LLC was paid $4.86M by Medicaid between Jan 2018 and Nov 2024, across 54 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoUHS OF OKLAHOMA, LLC
ENID, OK 73701
ENID, OK 73701
33aNPI1417947466assigned 10/21/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$4.86M
24GClaims54,457
24DCodes billed54
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,950 | $594K | |
| 2019 | 7,472 | $678K | |
| 2020 | 4,423 | $371K | |
| 2021 | 5,664 | $513K | |
| 2022 | 13,449 | $1.17M | |
| 2023 | 10,808 | $973K | |
| 2024incomplete | 5,691 | $554K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 6,324 | 6,235 | $1.51M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 9,178 | 9,104 | $1.47M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 3,557 | 3,519 | $1.11M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.8% | 2,205 | 2,157 | $280K |
| 36415 | Collection of venous blood by venipuncture | 2.7% | 9,585 | 8,706 | $130K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 350 | 199 | $59K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 112 | 112 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 887 | 854 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,426 | 4,963 | $36K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 305 | 304 | $28K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,969 | 1,930 | $24K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,435 | 748 | $21K |
42 more codes
| 80053 | Comprehensive metabolic panel | <1% | 2,312 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 186 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 105 | $11K |
| 97597 | <1% | 1,292 | $9K | |
| 80055 | <1% | 217 | $9K | |
| 81001 | <1% | 2,711 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,288 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 244 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 288 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 418 | $3K |
| 88312 | <1% | 40 | $3K | |
| 87653 | <1% | 91 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 371 | $3K |
| 86803 | <1% | 216 | $3K | |
| 81025 | <1% | 329 | $2K | |
| 84484 | <1% | 205 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 31 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 31 | $1K |
| 87430 | <1% | 94 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| 87081 | <1% | 206 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 38 | $1K |
| 81002 | <1% | 362 | $977.75 | |
| 83690 | <1% | 155 | $852.07 | |
| 83605 | <1% | 69 | $699.91 | |
| 87420 | <1% | 55 | $687.66 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 30 | $665.00 |
| 85027 | <1% | 124 | $661.25 | |
| 81003 | <1% | 310 | $625.83 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $561.78 |
| 82950 | <1% | 118 | $481.18 | |
| 82962 | <1% | 162 | $292.84 | |
| 85018 | <1% | 130 | $263.54 | |
| 85014 | <1% | 130 | $263.54 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $187.26 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $187.26 |
| 83735 | <1% | 18 | $107.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 229 | $95.76 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 378 | $70.50 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 42 | $46.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 13 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.